H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Xenetic Biosciences (XBIO – Research Report) today and set a price target of $4.00. The company's shares closed last Friday at $0.74, close to its 52-week low of $0.70. According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -29.2% and a 16.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xenetic Biosciences with a $4.00 average price target.
https://www.tipranks.com/news/blurbs/h-c-wainwright-maintains-their-buy-rating-on-xenetic-biosciences-xbio?utm_source=advfn.com&utm_medium=referral
Xenetic Biosciences (NASDAQ:XBIO)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Xenetic Biosciences Charts.
Xenetic Biosciences (NASDAQ:XBIO)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Xenetic Biosciences Charts.